CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Price, Quote, News and Overview
NASDAQ:CRBP - Nasdaq - US21833P3010 - Common Stock - Currency: USD
CRBP Quote, Performance and Key Statistics
7.23
-0.13 (-1.77%)
The current stock price of CRBP is 7.23 USD. In the past month the price increased by 0.42%. In the past year, price decreased by -83.11%.
CRBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.83 | 323.41B | ||
| AMGN | AMGEN INC | 13.41 | 149.70B | ||
| GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
| ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
| ONC | BEIGENE LTD-ADR | 6.15 | 25.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
| NTRA | NATERA INC | N/A | 22.01B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
| BIIB | BIOGEN INC | 8.06 | 18.69B |
Related stock screener links
About CRBP
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Company Info
CORBUS PHARMACEUTICALS HOLDI
500 River Ridge Drive
Norwood MASSACHUSETTS 02062 US
CEO: Yuval Cohen
Employees: 28
Phone: 16179630103
CORBUS PHARMACEUTICALS HOLDI / CRBP FAQ
What is the stock price of CORBUS PHARMACEUTICALS HOLDI today?
The current stock price of CRBP is 7.23 USD. The price decreased by -1.77% in the last trading session.
What is the ticker symbol for CORBUS PHARMACEUTICALS HOLDI stock?
The exchange symbol of CORBUS PHARMACEUTICALS HOLDI is CRBP and it is listed on the Nasdaq exchange.
On which exchange is CRBP stock listed?
CRBP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CORBUS PHARMACEUTICALS HOLDI stock?
16 analysts have analysed CRBP and the average price target is 53.15 USD. This implies a price increase of 635.18% is expected in the next year compared to the current price of 7.23. Check the CORBUS PHARMACEUTICALS HOLDI stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CORBUS PHARMACEUTICALS HOLDI worth?
CORBUS PHARMACEUTICALS HOLDI (CRBP) has a market capitalization of 88.50M USD. This makes CRBP a Micro Cap stock.
How many employees does CORBUS PHARMACEUTICALS HOLDI have?
CORBUS PHARMACEUTICALS HOLDI (CRBP) currently has 28 employees.
What are the support and resistance levels for CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?
CORBUS PHARMACEUTICALS HOLDI (CRBP) has a support level at 7.22 and a resistance level at 7.24. Check the full technical report for a detailed analysis of CRBP support and resistance levels.
Should I buy CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRBP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRBP, evaluating the profitability, health, valuation and growth aspects
- CORBUS PHARMACEUTICALS HOLDI (CRBP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CORBUS PHARMACEUTICALS HOLDI (CRBP) Sales and EPS estimates to see what analysts future expectations are.
- CORBUS PHARMACEUTICALS HOLDI (CRBP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CORBUS PHARMACEUTICALS HOLDI (CRBP) Insider and Institutional Ownership to learn about the owners and their transactions.
- CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Chart to make your own analysis
- CORBUS PHARMACEUTICALS HOLDI (CRBP) Latest news and press-releases to stay up to date.
Does CORBUS PHARMACEUTICALS HOLDI (CRBP) stock pay dividends?
CRBP does not pay a dividend.
When does CORBUS PHARMACEUTICALS HOLDI (CRBP) report earnings?
CORBUS PHARMACEUTICALS HOLDI (CRBP) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of CORBUS PHARMACEUTICALS HOLDI (CRBP)?
CORBUS PHARMACEUTICALS HOLDI (CRBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.22).
What is the Short Interest ratio of CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?
The outstanding short interest for CORBUS PHARMACEUTICALS HOLDI (CRBP) is 16.76% of its float. Check the ownership tab for more information on the CRBP short interest.
CRBP Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CRBP. When comparing the yearly performance of all stocks, CRBP is a bad performer in the overall market: 93.3% of all stocks are doing better.
CRBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRBP. CRBP has a great financial health rating, but its profitability evaluates not so good.
CRBP Financial Highlights
Over the last trailing twelve months CRBP reported a non-GAAP Earnings per Share(EPS) of -4.22. The EPS increased by 37.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.94% | ||
| ROE | -39.56% | ||
| Debt/Equity | 0 |
CRBP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to CRBP. The Buy consensus is the average rating of analysts ratings from 16 analysts.